These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27196567)

  • 1. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
    Gupta N; Hanley MJ; Harvey RD; Badros A; Lipe B; Kukreti V; Berdeja J; Yang H; Hui AM; Qian M; Zhang X; Venkatakrishnan K; Chari A
    Br J Haematol; 2016 Sep; 174(5):748-59. PubMed ID: 27196567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
    Gupta N; Hanley MJ; Venkatakrishnan K; Perez R; Norris RE; Nemunaitis J; Yang H; Qian MG; Falchook G; Labotka R; Fu S
    Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
    Salvini M; Troia R; Giudice D; Pautasso C; Boccadoro M; Larocca A
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):91-99. PubMed ID: 29235380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
    Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
    Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
    Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
    Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
    Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
    Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
    J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
    Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
    J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
    Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.